key: cord-0683011-t9zuwdec authors: Aghemo, Alessio; Piovani, Daniele; Parigi, Tommaso Lorenzo; Brunetta, Enrico; Pugliese, Nicola; Vespa, Edoardo; Omodei, Paolo Dario; Preatoni, Paoletta; Lleo, Ana; Repici, Alessandro; Voza, Antonio; Cecconi, Maurizio; Malesci, Alberto; Bonovas, Stefanos; Danese, Silvio title: Covid-19 digestive system involvement and clinical outcomes in a large academic hospital in Milan, Italy. date: 2020-05-11 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2020.05.011 sha: 982537ec4559e806841a0ac57d16e2a0b6240610 doc_id: 683011 cord_uid: t9zuwdec nan Since February 2020, the Covid-19 pandemic has spread to Italy affecting more than 100,000 people. Several studies have reported a high prevalence of gastrointestinal (GI) symptoms, and investigated their potential association with clinical outcomes. 1 The timing, clinical significance, and possible impact on viral spread, of GI symptoms presentation have not been fully elucidated. Elevation of liver function tests and other laboratory values has also been reported; however, their prognostic significance has not been clearly established. 2 We analyzed a cohort of RT-PCR-confirmed Covid-19 patients 3 consecutively admitted to Humanitas Hospital, Milan, Italy, to describe the prevalence of GI symptoms and GI/liver tests abnormalities, and their association with clinical outcomes. Clinical and laboratory data were extracted from electronic medical records (EMR). Presence of vomit and diarrhea (defined as passing of 3 or more loose stools per day) as reported at admission or during the week preceding admission, were recorded as per EMR. To explore the associations between GI clinical and laboratory parameters with clinical deterioration we used survival model for censored observations. The composite study endpoint was clinical deterioration defined as ICU transfer or death within 20 days of hospital admission. Time to event was defined as the time from hospital admission until the date of event or censoring. We used log-rank tests and Cox regression analysis. Missing data were not imputed. We presented hazard ratios (HR) with 95% confidence intervals (CI). From 22 February to 30 March 2020, 325 RT-PCR-confirmed Covid-19 patients had been admitted to the Humanitas Research Hospital. The analysis was restricted to 292 patients, after excluding those who were transferred to the ICU, or died, within the first day. Patients were predominantly males (68.2%) with a mean age of 65.0±14.1 years. Diarrhea (27.1%) was the most frequent GI symptom. Patients' characteristics are summarized in Table 1 . As of 30 March, 129 patients (44.2%) had been discharged, and 107 (36.6%) were still hospitalized. Clinical deterioration occurred in 82 patients (28.1%), including 27 (9.2%) patients who were transferred to ICU, and 56 (19.2%) who died. Among admission parameters, the presence of any GI symptom (i.e. diarrhea or vomit), alkaline phosphatase, total bilirubin, direct bilirubin and lipase levels were significantly associated with 'ICU transfer or death' in the univariable analyses (Supplementary Table 2 ). Of these, the occurrence of any GI symptom (adjusted hazard ratio [aHR] 0.47, 95% CI 0.23-0.97; p=0.041), alkaline phosphatase levels (aHR 1.14, 95% CI 1.05-1.23, per 100 U/L increase; p=0.001) and high lipase levels (aHR 2.02, 95% CI 1.08-3.80; p=0.028) remained significant after adjustment for age and sex (Supplementary Table 2 ). Importantly, the presence of GI symptoms was inversely associated with the risk of clinical deterioration, while higher levels of alkaline phosphatase and lipase predicted a poor prognosis. In a cohort of Covid-19 admitted patients, we found a high prevalence of GI symptoms. Interestingly, the presence of diarrhea or vomit were associated with a better prognosis, independently of patient age and sex. It is worth noting that we excluded patients admitted in critical conditions in whom a detailed medical history about gastrointestinal symptoms was not adequately assessed. Our findings could be explained by a prevalent GI viral localization rather than respiratory. Gastrointestinal tropism of SARS-CoV2 has been demonstrated in a recent study that detected SARS-CoV2 more frequently in the stools of patients presenting with diarrhea. 4, 5 We also found that elevated lipase and alkaline phosphatase levels were associated with poor prognosis; whether this reflects a greater systemic inflammatory response or an early sign of multiorgan failure needs to be ascertained. 6 Since ACE2 receptors are highly expressed by pancreatic islets, a possible direct cytopathic injury seems likely. 6 The action of Sars-CoV on the pancreas through these receptors can induce acute hyperglycemia and transient type-2-diabetes, 7 possibly leading to further complications and poor prognosis. The correlation we observed with alkaline phosphatase is intriguing as ACE2 receptors are also abundantly expressed on endothelial liver cells, which makes liver a potential target for SARS-CoV. 8 However, liver biopsies of Covid-19 patients have not shown signs of biliary tract damage or cholestasis, thus we cannot exclude that high alkaline phosphatase reflects bone diseases and systemic frailty. In conclusion, we observed that biochemical elevations of liver and GI tests as well as GI symptoms are common at presentation in hospitalized patients with Covid-19, with high lipase and alkaline phosphatase levels and the absence of vomit/diarrhea predicting poor clinical outcomes. Journal Pre-proof Effect of gastrointestinal symptoms on patients infected with COVID-19 Liver injury in COVID-19 : management and challenges Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Evidence for gastrointestinal infection of SARS-CoV-2 Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong Cohort and systematic review and metaanalysis Pancreatic injury patterns in patients with COVID-19 pneumonia Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Liver injury during highly pathogenic human coronavirus infections